sodium zirconium cyclosilicate: prescribing and clinical use
Focused clinical detail for use alongside current product information, local policy and patient-specific assessment.
sodium zirconium cyclosilicate: clinical details
Prescribing considerations
- Confirm hyperkalaemia and review its cause, concurrent medicines and dietary potassium intake.
- Consider the formulation's high sodium content in patients with heart failure, fluid overload or sodium restriction.
- Monitor patients with pre-existing heart failure for increasing dyspnoea, oedema and rapid weight gain.
- Safety and efficacy have not been established in people under 18 years.
- Alert radiology before abdominal imaging because the compound may be radiopaque.
Contraindications and cautions
- Hypersensitivity to sodium zirconium cyclosilicate.
- Use caution if intestinal perforation is suspected; the risk with this product is currently unknown.
- Severe hypokalaemia requires treatment interruption and clinical reassessment.
Monitoring
- Serum potassium when clinically indicated, after treatment adjustment and after changes to medicines affecting potassium.
- Clinical signs of fluid retention or worsening heart failure.
- Potassium trends in relation to kidney disease progression, dietary intake, dialysis and concurrent medicines.
Clinical pharmacology
A selective, insoluble, non-polymer inorganic cation exchanger that binds potassium throughout the gastrointestinal tract in exchange for hydrogen and sodium. It is not systemically absorbed or enzymatically metabolised and increases faecal potassium excretion.
Formulation and product differences
- The selected product is a white-to-grey powder for oral suspension supplied in sachets.
- The powder is insoluble and must be consumed as a cloudy suspension.
- The formulation contains no additional ingredients but has clinically relevant intrinsic sodium content.
sodium zirconium cyclosilicate preparations and strengths
Oral suspension
Route: Oral
Strengths: 5 g, 10 g
sodium zirconium cyclosilicate interactions
It can temporarily raise stomach pH and alter absorption of some oral medicines. Check administration timing with a pharmacist or prescriber.
Tacrolimus
Exposure may be reduced, so administration should be separated and transplant monitoring requirements followed.
Azole antifungals such as ketoconazole, itraconazole and posaconazole
Raised stomach pH may reduce or alter absorption, so administration should be separated.
Certain HIV treatments
Absorption of pH-dependent medicines such as atazanavir or rilpivirine may be altered, so administration should be separated.
Sources
These sources were used to prepare and review this medicine page.
Prepared and reviewed by the iatroX editorial team.